News
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biopharmaceutical company that develops treatments for eye disorders and other serious medical conditions, tumbled 10% during the....
ALPHA MOS : Informations relatives au nombre total de droits de vote
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Why DaVita Inc. Jumped Higher Today
DaVita (NYSE: DVA) is up 12.8% at 12:35 p.m. EST after announcing that it's selling its medical group to UnitedHealth Group's (NYSE: UNH) health services business Optum for $4.9 billion.....
Why Alnylam Pharmaceuticals Rose 12.7% in November
In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a clinical-stage biotech focused on RNAi therapies, jumped 13%....
Depomed Executes an Exit Strategy for Its Opioid Drug
After reporting that Collegium Pharmaceutical (NASDAQ: COLL) will take over commercializing its top-selling drug, Nucynta, Depomed Inc. (NASDAQ: DEPO) shares rallied 10% yesterday. The pact is....
Here's Why Editas Medicine Inc. Stock Is Slipping Today
Shares of Editas Medicine Inc. (NASDAQ: EDIT), a biotech that aims to correct disease‑causing genes with CRISPR technology, are in retreat following the pricing of a secondary share offering this....
The 2 Likely Reasons Novavax Inc. Rocketed Higher by 25% in November
Shares of Novavax (NASDAQ: NVAX), a clinical-stage small-cap biotech company focused on the development of recombinant nanoparticle vaccines, surged by 25% during the month of November, according....
2 Reasons Geron Corporation Took a Pounding in November
Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage biotech company focused on the development of oncology drugs, sank 12% during the month of November, according to data from S&P....
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
Veeva Systems Inc. (VEEV) Q3 2018 Earnings Conference Call Transcript
Image source: The Motley Fool.Veeva Systems Inc. (NYSE: VEEV)Q3 2018 Earnings Conference CallDec. 5, 2017, 4:30 p.m. ETOperatorContinue readingSource: Fool.com
3 Growth Stocks With Virtual Monopolies
Monopolies can be bad. Having a single company control every aspect of an entire industry is likely to lead to higher consumer prices, slower innovation, and anticompetitive behavior.Lucky for us,....
Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average....
Why Snap, Regal Entertainment Group, and Revance Therapeutics Jumped Today
Tuesday was a down day for most of the stock market, with major benchmarks finishing with modest losses of half a percent or less. The NYSE Composite pulled back from the record highs it reached....
Why Illumina Jumped 9.8% in November
Shares of the genomic sequencing specialist Illumina (NASDAQ: ILMN) rose nearly 10% in November, according to data from S&P Global Market Intelligence. However, there wasn't any....
Why Alexion Pharmacteuicals Sank 8.9% in November
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a commercial-stage biotech focused on rare diseases, fell 9% in November, according to data from S&P Global Market Intelligence. There doesn't....
MEDICREA : Declaration_des_droits_de_vote_AMF_30-11-2017
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
(Article L.233-8-II du Code de Commerce et Article 222-12-5 du règlement général de....
VISIOMED GROUP lève 2,6 MEUR pour poursuivre son développement dans la santé connectée
Paris, le 5 décembre 2017
VISIOMED GROUP (FR0011067669 – ALVMG), société spécialisée dans l'électronique médicale nouvelle génération, annonce la réalisation d'une augmentation de 2,6 M€ qui....
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
Shares of specialty pharmaceutical developer Collegium Pharmaceutical (NASDAQ: COLL) rose over 23% today after the company announced that it will acquire the pain drug Nucynta from Depomed....
Why Revance Therapeutics Is Soaring Today
In response to the company's strong results from two pivotal phase 3 trials, shares of Revance Therapeutics (NASDAQ: RVNC), a clinical-stage biotech focused on aesthetics, rose 36% as of 11:10....
MorphoSys: Partner erhält Medikamenten-Zulassung in Kanada
Der MorphoSys-Lizenzpartner Janssen hat in Kanada die Zulassung zur Behandlung erwachsener Patienten mit moderater bis schwerer Form von Schuppenflechte mit dem Medikament Tremfya erhalten. Das....
Why Nektar Therapeutics Shares Delivered a Stupendous 124% in November
After the company updated the timeline for filing its pain-relieving drug for approval from the Food and Drug Administration, and presented early-stage study results for its solid-tumor cancer....
3 Things Veeva Systems Inc. Shareholders Should Watch Going Into Earnings
Veeva Systems (NYSE: VEEV), which provides cloud solutions primarily to pharmaceutical companies, will be reporting earnings next week. While the stock has been a resounding success over the past....
What Happened in the Stock Market Today
Stocks began the day in positive territory thanks to optimism over the Senate's passage of a tax bill, but declined over the length of the session, ultimately ending with mixed results. The Dow....
Why Ra Pharmaceuticals, Inc. Got Hammered Today
Ra Pharmaceuticals (NASDAQ: RARX) characterized its interim phase 2 data testing RA101495 SC in patients with paroxysmal nocturnal hemoglobinuria (PNH) as "positive," but the market sees it....